GWENNE PRESSLER: Open Payments
NPI 1922357490 · MUSKEGON, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$658 in 35 payments from 17 companies in 2025. Trend: 2023 $484 · 2024 $411 · 2025 $658
Food & beverage: $639Education: $19
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $84 |
| ABBVIE INC. | 4 | $75 |
| Lilly USA, LLC | 4 | $74 |
| PFIZER INC. | 3 | $53 |
| GlaxoSmithKline, LLC. | 3 | $53 |
| Novo Nordisk Inc | 3 | $52 |
| Astellas Pharma US Inc | 2 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| AstraZeneca Pharmaceuticals LP | 1 | $23 |
Products named: CAPLYTA, MOUNJARO, UBRELVY, TRELEGY ELLIPTA, Veozah, REXULTI, Saxenda, FANAPT.
Industry payments across MI — which companies pay providers there.
